Repatha Pushtronex. Repatha® (evolocumab) Injection & Dosing Guide In addition to the 420 mg/3.5 mL single-dose Pushtronex, Repatha is available as a 140 mg/mL single-dose SureClick autoinjector and a 140 mg/mL single-dose prefilled syringe Patients continuing with Repatha treatment should be transitioned to either the single-dose prefilled syringe (140 mg/mL) or the single-dose prefilled SureClick ® autoinjector (140 mg/mL).
Wearable Injectors Market Forecast to 2030 MarketIndustryReports from www.pinterest.fr
The company is urging users to transition to the SureClick because it plans to discontinue the prefilled syringe in mid-2025 Amgen ® has made the decision to discontinue the Repatha ® Pushtronex ® System
Wearable Injectors Market Forecast to 2030 MarketIndustryReports
This decision was made globally to This decision was made globally to uphold the high standards that Amgen has set to enable the most optimal patient experience. Dear Repatha Patient, We want to inform you of an important update to our product portfolio Transitioning Patients to a New Device with a Prescription
Repatha® SureClick® Autoinjector. Dear Repatha Patient, We want to inform you of an important update to our product portfolio The patient should wait at least 30 minutes for the autoinjector to reach room temperature before injecting
How to Use Repatha with Pushtronex® System YouTube. There are no concerns about the Repatha ® drug product, efficacy, or patient safety • Repatha® Pushtronex® System is discontinued, to be followed by the discontinuation of the prefilled syringe mid-2025